Get the Stockscreener App
44.97
0.46%
-0.21
Guardant Health Inc stock is traded at $44.97, with a volume of 1.82M.
It is down -0.46% in the last 24 hours and up +4.83% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$45.18
Open:
$44.79
24h Volume:
1.82M
Relative Volume:
0.83
Market Cap:
$5.57B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-10.61
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+9.31%
1M Performance:
+4.83%
6M Performance:
+117.46%
1Y Performance:
+174.37%
1-Day Range:
$43.94
$45.11
1-Week Range:
$40.77
$46.78
52-Week Range:
$15.81
$50.89
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
44.97 | 5.57B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health price target raised to $60 from $56 at BofA - Yahoo Finance
Guardant Health (GH) Price Target Increased by BofA Amid Sector Challenges | GH Stock News - GuruFocus
BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating - marketscreener.com
Lobbying Update: $15,500 of GUARDANT HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Guardant Health to Report First Quarter 2025 Financial Results o - GuruFocus
Circulating Cell-Free Tumor DNA Market Detailed In New Research - openPR.com
S&P 500 Futures Up in Premarket Trading; Guardant Health, Brookfield Wealth Solns Lead - Barron's
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025 - The Joplin Globe
Mizuho Initiates Coverage of Guardant Health (GH) with Outperform Recommendation - MSN
Barclays Adjusts Guardant Health (GH) Price Target Amid Sector C - GuruFocus
Mizuho Initiates Guardant Health at Outperform - MarketScreener
Guardant Health secures facility lease extension through 2031 By Investing.com - Investing.com Canada
‘Preparing For Regulatory Milestones, Commercial Launch’ Are Priorities, Says New Freenome CEO Aaron Elliott - insights.citeline.com
Guardant Health (GH) Receives Outperform Rating from Mizuho with Strong Growth Prospects | GH Stock News - GuruFocus
Guardant Health secures facility lease extension through 2031 - Investing.com
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH) - Yahoo Finance
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Guardant Health partners with Bayshore for cancer tests in Canada By Investing.com - Investing.com South Africa
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada - 01net
Guardant Health partners with Bayshore for cancer tests in Canada - Investing.com
Guardant Health And Bayshore Healthcare Partner To Expand Access To Advanced Precision Oncology Testing In Canada - MarketScreener
A More Convenient Way to Get Screened for Colon Cancer - Sunnyside Sun
(GH) Trading Advice - news.stocktradersdaily.com
4 Healthcare Stocks With Massive Gains—and More to Come - MarketBeat
Guardant Health’s Strategic Growth: Shield’s Coverage Expansion and Revenue Potential - TipRanks
Clinical Applications of ctDNA in Colorectal Cancer: Where Do We Stand? - ASCO Daily News
Liquid Biopsy Market Insights and Projections 2025-2032 - openPR
VA expands coverage to include CRC blood test for veterans By Investing.com - Investing.com Australia
VA expands coverage to include CRC blood test for veterans - Investing.com India
Guardant Health shares rise on VA coverage for cancer test By Investing.com - Investing.com South Africa
Guardant Health shares rise on VA coverage for cancer test - Investing.com
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries - Yahoo Finance
Key Market Driver in Breast Cancer Liquid Biopsy Industry 2025: Rising Breast Cancer Cases Fuel Demand For ... - WhaTech
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Guardant Health director Tariq Musa sells $5,069 in stock By Investing.com - Investing.com South Africa
Guardant Health director Tariq Musa sells $5,069 in stock - Investing.com India
1 Healthcare Stock on Our Watchlist and 2 to Turn Down - Yahoo Finance
AI Healthcare Co. Accuses Test-Maker Of Infringing Patents - Law360
AI Health Care Co. Accuses Test-Maker Of Infringing Patents - Law360
Creating awareness for Colorectal Cancer Month - WFLA
Guardant Accused of Infringing Tempus AI Cancer Research Tech - Bloomberg Law News
Guardant Accused of Copying Tempus AI Cancer Research Tech (1) - Bloomberg Law News
Liquid biopsy market flooded with opportunity - BioWorld Online
Guardant Health rises after Medicare ADLT status for colorectal cancer test - MSN
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation - Seeking Alpha
Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics By Investing.com - Investing.com UK
Guardant Health’s ADLT Status Boosts Shield CRC Test’s Market Position and Financial Outlook - TipRanks
1,415 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by SBI Securities Co. Ltd. - Defense World
Investing in Guardant Health (NASDAQ:GH) a year ago would have delivered you a 129% gain - Simply Wall St
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):